Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
Question
Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
Direct answer
Biohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm. — bullish pressure on BHVN.
- Original publisher
- Market Ontology
- Evidence through
- 2026-08-28
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim”, revision 1, evidence through 2026-08-28. https://marketontology.com/catalysts/2026-08-28/biohaven-secures-795m-licensing-pact-with-sk-biopharmaceuticals-for-opakalim-d2e4be
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| BHVN | ▲Bull | 1–4 weeks | Catalyst Driven | 73 |
Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for Opakalim
Biohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm. — bullish pressure on BHVN.
Biohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm.
- SummaryBiohaven entered into a major global licensing agreement with SK Biopharmaceuticals valued at up to $795 million. The partnership focuses on the commercialization and clinical development of Biohaven's Kv7 ion channel platform, led by drug candidate opakalim for focal epilepsy. The agreement transfers selective development and commercialization rights while injecting potential development and commercial milestone capital into Biohaven. This milestone structure reduces near-term equity financing dilution risk for the clinical-stage biotech firm.
- BHVNDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- BHVN closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- BHVN price vs. pre-event level
- BHVN volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
- 2026-08-28Biohaven partners with SK Biopharmaceuticals in $795M licensing dealBHVN
- 2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for OpakalimBHVN
- 2026-08-28Biohaven partners with SK Biopharmaceuticals in $795M licensing dealBHVN
- 2026-08-28Biohaven Secures $795M Licensing Pact With SK Biopharmaceuticals for OpakalimBHVN
- 2026-08-28Biohaven Signs $795M Licensing Deal with SK Biopharm for OpakalimBHVN XBI+0.88%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.